YMed Atlas
Clinical reference
Clinical reference
Ophthalmic, VEGF inhibitor · Humanized anti–VEGF-A monoclonal antibody fragment · Neonatology, Ophthalmology, Pediatrics
VEGF-A inhibitor for intravitreal use. Type 1 retinopathy of prematurity (ROP): 0.12–0.3 mg (0.02–0.03 mL) per eye; studies used 0.25 mg/0.025 mL, 0.3 mg/0.03 mL, or 0.12 mg/0.02 mL, 0.2 mg/0.02 mL. Premedicate with anesthesia and antiseptic; post-op antibiotic drops 7 days. Pediatric safety/effectiveness not established.